文献速递肾移植

AA型淀粉样变性患者的肾移植:法国多中心队列结局

Kidney Transplantation in Patients With AA Amyloidosis: Outcomes in a French Multicenter Cohort.
PubMed 文献 · Am J Kidney Dis · 2023-09-22

该回顾性多中心队列纳入2008–2018年法国26个中心86例因AA淀粉样变性接受肾移植的患者,中位年龄49.4岁,家族性地中海热为最主要病因(37例,43%)。移植后1年患者生存率94.0%(95%CI 89.1–99.2),5年85.5%(77.8–94.0);同种异体移植物丢失累积发生率1年10.5%(4.0–17.0),5年13.0%(5.8–20.1)。组织学证实的AA淀粉样变性复发见于5例移植肾(5.8%)。

要点

  • 该队列移植后5年患者生存率85.5%,移植物丢失累积发生率13.0%。
  • 组织学证实的AA淀粉样变性移植肾复发率为5.8%。
  • 移植时C反应蛋白浓度与患者生存(HR 1.01)及移植物生存(HR 1.68)相关。

核心结论

  • 该相对当代队列中因AA淀粉样变性接受肾移植的患者获得了较好的生存率和较既往报告更低的复发率。
  • 这些数据支持对AA淀粉样变性所致终末期肾病患者进行肾移植实践。

研究设计与样本

  • 回顾性多中心队列研究,检索法国国家移植数据库纳入2008–2018年因肾AA淀粉样变性接受肾移植的患者。
  • 共纳入86例在法国26个中心接受肾移植的患者,中位年龄49.4岁(IQR 39.7–61.1)。

主要发现

  • 患者生存率移植后1年94.0%(95%CI 89.1–99.2),5年85.5%(77.8–94.0)。
  • 同种异体移植物丢失累积发生率1年10.5%(4.0–17.0),5年13.0%(5.8–20.1)。
  • 组织学证实的AA淀粉样变性复发见于5例移植肾(5.8%)。
  • 需住院治疗的感染发生率为55.8%,急性同种异体排斥反应发生率为27.9%。
  • 多变量分析显示移植时C反应蛋白浓度与患者生存相关(HR 1.01;95%CI 1.00–1.02;P=0.01),与移植物生存相关(HR 1.68;95%CI 1.10–2.57;P=0.02)。

关键数值与推荐

  • 家族性地中海热为最主要病因(37例,43%)。
  • 移植后接受生物治疗者16例(18.6%)。

临床怎么用

  • 原文结论指出这些数据支持对AA淀粉样变性所致终末期肾病患者进行肾移植实践。

局限性

  • 研究缺乏对照组。
  • 无法探讨生物治疗对移植结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Outcomes of kidney transplantation for patients with renal AA amyloidosis are uncertain, with reports of poor survival and high rates of disease recurrence. However, the data are inconclusive and mostly based on studies from the early 2000s and earlier. STUDY DESIGN: Retrospective multicenter cohort study. SETTING & PARTICIPANTS: We searched the French national transplant database to identify all patients with renal AA amyloidosis who underwent kidney transplantation between 2008 and 2018. EXPOSURES: Age, cause of amyloidosis, use of biotherapies, and C-reactive protein levels. OUTCOMES: Outcomes were all-cause mortality and allograft loss. We also reported amyloidosis allograft recurrence, occurrence of acute rejection episodes, as well as infectious, cardiovascular, and neoplastic disease events. ANALYTICAL APPROACH: Kaplan-Meier estimator for mortality and cumulative incidence function method for allograft loss. Factors associated with patient and allograft survival were investigated using a Cox proportional hazards model and a cause-specific hazards model, respectively. RESULTS: 86 patients who received kidney transplants for AA amyloidosis at 26 French centers were included. The median age was 49.4 years (IQR, 39.7-61.1). The main cause of amyloidosis was familial Mediterranean fever (37 cases; 43%). 16 (18.6%) patients received biotherapy after transplantation. Patient survival rates were 94.0% (95% CI, 89.1-99.2) at 1 year and 85.5% (77.8-94.0) at 5 years after transplantation. Cumulative incidences of allograft loss were 10.5% (4.0-17.0) at 1 year and 13.0% (5.8-20.1) at 5 years after transplantation. Histologically proven AA amyloidosis recurrence occurred in 5 transplants (5.8%). An infection requiring hospitalization developed in 55.8% of cases, and there was a 27.9% incidence of acute allograft rejection. Multivariable analysis showed that C-reactive protein concentration at the time of transplantation was associated with patient survival (HR, 1.01; 95% CI, 1.00-1.02; P=0.01) and allograft survival (HR, 1.68; 95% CI, 1.10-2.57; P=0.02). LIMITATIONS: The study lacked a control group, and the effect of biotherapies on transplantation outcomes could not be explored. CONCLUSIONS: This relatively contemporary cohort of patients who received a kidney transplant for AA amyloidosis experienced favorable rates of survival and lower recurrence rates than previously reported. These data support the practice of treating these patients with kidney transplantation for end-stage kidney disease. PLAIN-LANGUAGE SUMMARY: AA amyloidosis is a severe and rare disease. Kidney involvement is frequent and leads to end-stage kidney disease. Because of the involvement of other organs, these patients are often frail, which has raised concerns about their suitability for kidney transplantation. We reviewed all patients with AA amyloidosis nephropathy who underwent kidney transplantation in France in the recent era (2008-2018) and found that the outcomes after kidney transplantation were favorable, with 85.5% of patients still alive 5 years after transplantation, a survival rate that is comparable to the outcomes of patients receiving a transplant for other forms of kidney diseases. Recurrence of amyloidosis in the transplanted kidney was infrequent (5.8%). These data support the practice of kidney transplantation for patients with AA amyloidosis who experience kidney failure.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Schwarz C, Georgin-Lavialle S, Lombardi Y, et al. Kidney Transplantation in Patients With AA Amyloidosis: Outcomes in a French Multicenter Cohort. Am J Kidney Dis. 2023. PMID: 37741608. doi:10.1053/j.ajkd.2023.07.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。